Stay updated on Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Version updated from v3.0.1 to v3.0.2, indicating a new release in the core content. The 'Back to Top' element was removed, with no other substantive changes detected.
    Difference
    0.1%
    Check dated 2025-09-13T17:11:02.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-09-06T14:55:46.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the addition of a facility name and location, as well as the introduction of new drug names such as Eribulin Mesylate and Pembrolizumab. However, several related topics and terms have been removed, including previous mentions of Eribulin and Pembrolizumab.
    Difference
    2%
    Check dated 2025-08-30T11:44:39.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    The web page has been updated from version v2.16.11 to v2.16.12.
    Difference
    0.1%
    Check dated 2025-08-16T04:36:25.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.10 to version 2.16.11.
    Difference
    0.1%
    Check dated 2025-08-08T23:50:59.000Z thumbnail image
  7. Check
    48 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.
    Difference
    0.7%
    Check dated 2025-08-01T19:19:25.000Z thumbnail image

Stay in the know with updates to Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.